National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report
- PMID: 27713091
- PMCID: PMC5378687
- DOI: 10.1016/j.bbmt.2016.09.025
National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report
Abstract
Hematopoietic cell transplantation (HCT) survivors are at risk for development of late complications and require lifelong monitoring for screening and prevention of late effects. There is an increasing appreciation of the issues related to healthcare delivery and coverage faced by HCT survivors. The 2016 National Institutes of Health Blood and Marrow Transplant Late Effects Initiative included an international and broadly representative Healthcare Delivery Working Group that was tasked with identifying research gaps pertaining to healthcare delivery and to identify initiatives that may yield a better understanding of the long-term value and costs of care for HCT survivors. There is a paucity of literature in this area. Critical areas in need of research include pilot studies of novel and information technology supported models of care delivery and coverage for HCT survivors along with development and validation of instruments that capture patient-reported outcomes. Investment in infrastructure to support this research, such as linkage of databases including electronic health records and routine inclusion of endpoints that will inform analyses focused around care delivery and coverage, is required.
Keywords: Care delivery models; Healthcare value; Hematopoietic cell transplantation; Late Effects Consensus Conference; National Institutes of Health; Survivorship.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.Biol Blood Marrow Transplant. 2017 Apr;23(4):538-551. doi: 10.1016/j.bbmt.2016.09.011. Epub 2016 Sep 19. Biol Blood Marrow Transplant. 2017. PMID: 27660168 Free PMC article. Review.
-
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.Biol Blood Marrow Transplant. 2017 Jan;23(1):6-9. doi: 10.1016/j.bbmt.2016.10.020. Epub 2016 Oct 29. Biol Blood Marrow Transplant. 2017. PMID: 27989931 Free PMC article.
-
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.Biol Blood Marrow Transplant. 2017 Jan;23(1):10-23. doi: 10.1016/j.bbmt.2016.08.018. Epub 2016 Aug 30. Biol Blood Marrow Transplant. 2017. PMID: 27590102 Free PMC article. Review.
-
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.Biol Blood Marrow Transplant. 2017 Mar;23(3):367-378. doi: 10.1016/j.bbmt.2016.09.005. Epub 2016 Sep 12. Biol Blood Marrow Transplant. 2017. PMID: 27634019 Free PMC article.
-
Managing Survivorship after Hematopoietic Cell Transplantation.Curr Hematol Malig Rep. 2023 Jun;18(3):75-82. doi: 10.1007/s11899-023-00694-8. Epub 2023 Mar 30. Curr Hematol Malig Rep. 2023. PMID: 36995660 Free PMC article. Review.
Cited by
-
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.Haematologica. 2019 May;104(5):1084-1092. doi: 10.3324/haematol.2018.203919. Epub 2018 Dec 4. Haematologica. 2019. PMID: 30514795 Free PMC article. Clinical Trial.
-
Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.Transplant Cell Ther. 2021 Mar;27(3):222-229. doi: 10.1016/j.jtct.2020.10.002. Epub 2020 Dec 21. Transplant Cell Ther. 2021. PMID: 33928266 Free PMC article. Review.
-
Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation.Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):70-77. doi: 10.1016/j.clml.2019.11.008. Epub 2019 Nov 13. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31810888 Free PMC article.
-
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.Blood Adv. 2020 May 12;4(9):2084-2094. doi: 10.1182/bloodadvances.2019000839. Blood Adv. 2020. PMID: 32396620 Free PMC article.
-
Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.Biol Blood Marrow Transplant. 2019 Jun;25(6):1240-1246. doi: 10.1016/j.bbmt.2019.02.003. Epub 2019 Feb 11. Biol Blood Marrow Transplant. 2019. PMID: 30763727 Free PMC article.
References
-
- IOM (Institute of Medicine) Delivering high-quality cancer care: Charting a new course for a system in crisis. Washington, DC: The National Academies Press; 2013. - PubMed
-
- IOM (Institute of Medicine) From cancer patient to cancer survivor: Lost in transition. Washington, DC: The National Academies Press; 2005.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical